Mandated Venous Thromboembolism Prophylaxis: Possible Adverse Outcomes
Section snippets
Materials and Methods
Mandated VTE prophylaxis, which included the use of both LMWH and warfarin, was instituted in July 2005 in our institution, an academic medical center with 600 inpatient beds. Regardless of risk of bleeding or risk of VTE, all patients undergoing THA were given warfarin (target INR of 2.0) starting on the day of surgery and 40 mg LMWH subcutaneously daily starting 12 hours after surgery. Patients undergoing TKA were given warfarin (target INR of 2.0) and were also given 40 mg LMWH if they had a
Administrative Data Analysis
The number of cases with the primary procedure of joint arthroplasty has increased from 586 cases in fiscal year 2005 to 759 cases in fiscal year 2007. Reported complications of any type (as indicated by the inclusion of any ICD-9 code in the range of 996.00 to 999.99 in the official patient record), including those not related to the orthopedic procedure, have increased from 22.7% to 31.4% of cases in the same period. The rate for readmission for reasons related directly to the orthopedic
Discussion
This study was undertaken to examine the increasing number of bleeding events that were occurring in joint arthroplasty patients after the introduction of mandatory VTE prophylaxis guidelines. We found a significant and alarming jump in the number of bleeding complications (hematoma, seroma, hemorrhage) after starting more aggressive anticoagulant therapy that included LMWH. A return to less aggressive therapy led to decreased rates of bleeding events in the 6 months after the policy change,
Acknowledgment
The authors would like to acknowledge Vince Gomez, University of Virginia, for his help with this manuscript.
References (23)
- et al.
Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis
J Arthroplasty
(2007) - et al.
Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty
J Arthroplasty
(1997) - et al.
Does excessive anticoagulation predispose to periprosthetic infection?
J Arthroplasty
(2007) - et al.
Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program
J Orthop Res
(2002) - et al.
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest
(2004) - et al.
Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030
J Bone Joint Surg Am
(2007) - et al.
Fatal vascular outcomes following major orthopedic surgery
Thromb Haemost
(2005) - et al.
Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study
J Bone Joint Surg Br
(2005) - et al.
Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999
Acta Orthop Scand
(2002) - et al.
Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials
Haemostasis
(1997)
Mechanical prophylaxis of deep-vein thrombosis after total hip replacement: a randomised clinical trial
J Bone Joint Surg Br
Cited by (0)
No benefits or funds were received in support of the study.